Infectious Disease Diagnostic Testing: World Market Analysis of TB, Flu, HIV, Hepatitis, Strep A, Malaria, HPV, Blood Screening, STDs, ID/AST, HAI, Rapids and Other Test Products

Infectious Disease Testing: World Market Analysis (HIV, Hepatitis, Blood Screening

With over 400 tables to illustrate the analysis and provide solid business planning metrics, The World Market for Infectious Disease Diagnostic Diagnostics Testing, covers 30 areas of infectious diseases in 25 countries and regions.  Diseases and technology categories segmented and forecasted in this report include:

• Blood Screening Immunoassay
• Blood Screening NAT
• Influenza Tests
• Strep A Test
• RSV Testing
• Malaria Tests
• Dengue Testing
• HIV Tests – Laboratories
• HIV Tests – POC
• Hepatitis Testing, Lab-Based
• Hepatitis Testing, POC
• STD Testing
• HPV Testing
• TORCH Testing
• TB Labs
• TB POC
• ID/AST Market, Auto
• ID/AST, Manual
• Blood Culture
• Chromogenic Media
• Rapid Micro
• Sepsis
• MRSA
• C. diff
• VRE
• Other HAI
• Parasitology
• Mycology
• Emerging Infectious Disease Tests
• Home OTC
• Other

For each of these product segments, the report provides a market size and forecast 2017-2025 for the following countries:

• United States
• Canada
• Germany
• France
• Spain
• UK
• Other Western Europe
• Australia
• Japan
• China
• Eastern Europe
• South Africa
• Indonesia
• Malaysia
• Singapore
• India
• Saudi Arabia
• Turkey
• Russia
• Taiwan
• South Korea
• Brazil
• Chile
• Columbia
• Other LATAM
• ROW

In addition, the report provides

• Global Market Sizing 
• Forecasts to 2025
• Company Profiles of Key Infectious Disease Testing Players
• Assessment of Infectious Disease Trends by Country
• Overview of Types of Testing
• Molecular Segmentation for key areas (HPV, HIV and Hepatitis)
• POC Segmentation for key areas (Hepatitis, HIV, Rapid Micro, TB, Self Testing)

Managed care in the United States and other developed countries demands quicker and more specific test results for infectious diseases. Rapid, near-patient testing can be used to rationalize antimicrobial usage and reduce repeat physician office visits. However, cost improvements are needed to widen the role of test products used in POC and POL settings as decentralized testing is disproportionately affected by cuts to reimbursements and pricing pressure on laboratory services and diagnostic procedures. Increased funding for infectious disease diagnostics from international governmental, non-governmental and non-profit health organizations is assisting in the development of a new generation of sophisticated test platforms designed to meet the needs of testing in low-resource environments (electricity, water, refrigeration, other environmental control, and personnel).